TWD
MLYS icon

True Wealth Design’s Mineralys Therapeutics MLYS Stock Holding History

True Wealth Design’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.91K Hold
76
– – ﹤0.01% 1696
2026
Q2 		$2.05K Hold
76
– – ﹤0.01% 1683
2026
Q1 		$2.06K Hold
76
– – ﹤0.01% 1530
2025
Q4 		$2.76K Hold
76
– – ﹤0.01% 1329
2025
Q3 		$2.88K Hold
76
– – ﹤0.01% 1329
2025
Q2 		$1.03K Buy
+76
New +$1.1K ﹤0.01% 1450

Other funds holding MLYS

AP
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
FIA
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

True Wealth Design's MLYS Position: Q3 2026 in Review

True Wealth Design held its Mineralys Therapeutics (MLYS) position steady in Q3 2026 at 76 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #1696.

True Wealth Design first reported a position in MLYS in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.88K in Q3 2025. 11 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • True Wealth Design held 76 shares of Mineralys Therapeutics worth $1.91K as of Q3 2026.
  • True Wealth Design left its Mineralys Therapeutics share count unchanged in Q3 2026.
  • Mineralys Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #1696 holding.
  • True Wealth Design first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • True Wealth Design's Mineralys Therapeutics position peaked at $2.88K in Q3 2025.
  • 11 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.